Development of small molecule inhibitors of the Pseudomonas aeruginosa biofilms to treat chronic infections in cystic fibrosis patients (360G-Wellcome-106310_Z_14_B)

£116,882
Recipient Organization

Cystic fibrosis is the most common lethal, hereditary disease in Caucasian populations, affecting 1 in every 3,500 births in Europe with a current life expectancy of about 38 years. Most disease-related morbidity and mortality in CF is caused by progressive lung disease as a result of bacterial infection and airway inflammation, primarily associated with the effects of chronic Pseudomonas aeruginosa (PA) lung infection and the persistence of PA biofilms. The Trust has awarded Antabio €4.0m over 2 years to fund the development of a small molecule inhibitor of PA biofilms to be used in combination with standard-of-care antibiotics. The objective of the project team, led by Principal Investigator Dr Martin Everett, Head of Biology at Antabio, is to identify a potent and selective lead series with efficacy in animals which will be capable of further development into a drug to augment the effectiveness of antibiotic therapy and result in enhanced suppression of the infection.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 116882
Applicant Surname Everett
Approval Committee Seeding Drug Discovery Committee
Award Date 2017-10-01T00:00:00+00:00
Financial Year 2017/18
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 106310/Z/14/B
Lead Applicant Dr Martin Everett
Partnership Value 116882
Planned Dates: End Date 2017-05-31T00:00:00+00:00
Planned Dates: Start Date 2017-05-01T00:00:00+00:00
Recipient Org: Country France
Region International